Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus

Qi, Xiaojuan; Li, Ling; Yang, Gangyi; Liu, Jianlei; Li, Ké; Tang, Yi; Liou, Hua; Boden, Guenther

doi:10.1111/j.1365-2265.2007.02776.x

Cited by 53 publications

(40 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these findings were in agreement with a previous study (Qi et al 2007), which found that obestatin levels correlated inversely and significantly with BMI (P = 0.035), insulin (P = 0.003) and HOMA-IR (P = 0.031) values, and did not correlate significantly with age (P = 0.162) nor glucose (P = 0.162) in diabetic patients (but their patients were not obese) [20] A study by Ma et al 2014 found that plasma obestatin concentrations in diabetic patients were significantly lower than those in normal glucose tolerance subjects. This is consistent with our results, although, all their subjects were middle-aged (41-64 years) and old (65-76 years) and they were not obese, and they showed that plasma ghrelin was negatively associated with fasting glucose and Urine Albumin-to-Creatinine Ratio (UACR), so that the lower ghrelin levels might be a potential indicator for renal dysfunction in patients with T2D [21].…”

Section: Discussionsupporting

confidence: 65%

Relation of Plasma Obestatin Levels with BMI and HOMA-IR in Syrian Obese Patients with Type 2 Diabetes

Alhalbouni¹,

Kabalan²,

Al-Quobaili³

2017

TOPHJ

View full text Add to dashboard Cite

Background:Obestatin is a novel hormone derived from preproghrelin, which was reported to inhibit appetite and gastric motility. Study Aim:This study aimed to investigate plasma obestatin levels in obese patients with T2D patients, which had not been studied clearly in last researches. Methods:23 normal weight subjects, 35 obese subjects and 31 obese patients with T2D participated in the study, the body mass index was calculated. Fasting glucose and insulin levels were measured and the homeostasis model assessment of insulin resistance (HOMA-IR) was determined. Plasma obestatin levels were measured with enzyme-linked immune sorbent assay (ELISA). The relationship between plasma obestatin levels and biochemical parameters was also analyzed. Results:Fasting obestatin was significantly lower in obese patients with T2D, comparing to control subjects (mean=6.35 vs12.38ng/ml) and to the non-patients obese group (mean=6.35 vs 7.76 ng/ml). Obestatin levels correlated significantly and negatively with BMI (R=-0. 451; P=0. 01), basal insulin levels (R=-0.737, P<0.0001) and HOMA-IR (R=-0. 764, P<0.0001) in diabetic patients. Conclusion:Our results suggest that obestatin may contribute to body weight regulation, and insulin sensitivity could be affected by obestatin levels.

show abstract

Section: Discussionsupporting

confidence: 65%

Relation of Plasma Obestatin Levels with BMI and HOMA-IR in Syrian Obese Patients with Type 2 Diabetes

Alhalbouni¹,

Kabalan²,

Al-Quobaili³

2017

TOPHJ

View full text Add to dashboard Cite

show abstract

“…Using different prohormone convertases, Zhu et al were not able to observe the formation of obestatin from proghrelin [53]. In addition, plasma obestatin levels measured by radioimmunoassay (RIA) led to varying results which might indicate that the low specificity of these tests could be due to lacking standardization and imprecise values in previous studies [19,36].…”

Section: Discussionmentioning

confidence: 99%

Peripheral obestatin has no effect on feeding behavior and brain Fos expression in rodents

et al. 2008

View full text Add to dashboard Cite

Obestatin is produced in the stomach from proghrelin by post-translational cleavage. The initial report claimed anorexigenic effects of obestatin in mice. Contrasting studies indicated no effect of obestatin on food intake (FI). We investigated influences of metabolic state (fed/fasted), environmental factors (dark/light phase) and brain Fos response to intraperitoneal (ip) obestatin in rats, and used the protocol from the original study assessing obestatin effects in mice. FI was determined in male rats injected ip before onset of dark or light phase, with obestatin (1 or 5 μmol/kg), CCK8S (3.5 nmol/kg) or 0.15 M NaCl, after fasting (16 h, n = 8/group) or ad libitum (n = 10-14/group) food intake. Fos expression in hypothalamic and brainstem nuclei was examined in freely fed rats 90 min after obestatin (5 μmol/kg), CCK8S (1.75 nmol/kg) or 0.15 M NaCl (n = 4/group). Additionally, fasted mice were injected ip with obestatin (1 μmol/kg) or urocortin 1 (2 nmol/kg) 15 min before food presentation. No effect on FI was observed after obestatin administration during the light and dark phase under both metabolic conditions while CCK8S reduced FI irrespectively of the conditions. The number of Fos positive neurons was not modified by obestatin while CCK8S increased Fos expression in selective brain nuclei. Obestatin did not influence the refeeding response to a fast in mice, while urocortin was effective. Therefore, peripheral obestatin has no effect on FI under various experimental conditions and did not induce Fos in relevant central neuronal circuitries modulating feeding in rodents.

show abstract

“…It was originally suggested that obestatin binds to the orphan G protein-coupled receptor (GPR), named GPR39 (17). Increased obestatin, decreased ghrelin levels and a decreased ghrelin/obestatin ratio characterize obesity in women (18), and plasma obestatin levels are low in patients with type 2 diabetes mellitus and impaired glucose intolerance (19). Both obestatin and ghrelin levels are increased in anorexic subjects and decreased in human obesity, suggesting that obestatin is a nutritional marker reflecting body adiposity and insulin resistance.…”

Section: Various Formsmentioning

confidence: 99%

The role of ghrelin in energy homeostasis and its potential clinical relevance (Review)

Cheng

Li²,

Asakawa³

et al. 2010

Int J Mol Med

View full text Add to dashboard Cite

Abstract. The novel gastric hormone ghrelin, a 28-amino acid peptide, has been identified as a potent growth-hormone secretagogue. Ghrelin production is regulated by nutritional and hormonal factors. Besides stimulating growth hormone secretion, studies show that ghrelin exerts a number of central and peripheral actions such as the regulation of food intake, the control of energy balance, glucose metabolism and insulin release, cardiovascular actions, the stimulation of gastric acid secretion, and motility. The broad spectrum of biological activities associated with ghrelin continues to expand. In the future, the diverse functions of ghrelin raise the possibility of its clinical application in a large number of pathological conditions.

show abstract

Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus

Abstract: Our results suggest that obestatin may play a role in appetite regulation in patients with IGR and T2DM.

Cited by 53 publications

References 12 publications

Relation of Plasma Obestatin Levels with BMI and HOMA-IR in Syrian Obese Patients with Type 2 Diabetes

Relation of Plasma Obestatin Levels with BMI and HOMA-IR in Syrian Obese Patients with Type 2 Diabetes

Peripheral obestatin has no effect on feeding behavior and brain Fos expression in rodents

The role of ghrelin in energy homeostasis and its potential clinical relevance (Review)

Contact Info

Product

Resources

About